Unexpected expression of the 250 kD melanoma-associated antigen in human sarcoma cells

Godal, Aslak; Bruland, Øyvind S.; Haug, Erik Skaaheim; Aas, Magne; Fodstad, Øystein

doi:10.1038/bjc.1986.142

Cited by 23 publications

(16 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The high affinity mAb 9.2.27 (obtained from Dr. R. Reisfeld, Scripps Research Institute, La Jolla, CA), originally developed against melanoma (38), recognizes an epitope on the high molecular weight melanoma-associated antigen. 9.2.27 has been shown to bind also some subgroups of sarcoma, including osteosarcoma (39). Both mAbs have previously been shown nonreactive with mononuclear cells in peripheral blood and bone marrow from normal donors (34,39) and react poorly with fibroblastically differentiated osteosarcoma.…”

Section: Methodsmentioning

confidence: 99%

“…9.2.27 has been shown to bind also some subgroups of sarcoma, including osteosarcoma (39). Both mAbs have previously been shown nonreactive with mononuclear cells in peripheral blood and bone marrow from normal donors (34,39) and react poorly with fibroblastically differentiated osteosarcoma. 4 In addition, the MRK-16 mAb (Alexis Corp., Kamiya Biomedical Co., Seattle, WA) binding the multidrug resistance-associated p-glycoprotein 170 (MDR1), and the anti-melanoma mAb EP-1 (kindly provided by Dr. P.G.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Hematogenous Micrometastases in Osteosarcoma Patients

Bruland

Høifødt

Sæter³

et al. 2005

Clinical Cancer Research

100

View full text Add to dashboard Cite

Bone marrow and peripheral blood samples from 60 patients with suspected bone sarcoma were examined for the presence and number of micrometastatic osteosarcoma cells by a sensitive immunomagnetic detection assay, using in parallel two osteosarcoma-associated antibodies. Forty-nine of the patients had osteosarcoma, and of these, as many as 31 (63%) had tumor cells in bone marrow, in many cases with a high number of cells. Only four (8%) were positive also in blood. None of 38 control bone marrow samples were positive, including 11from patients with suspected bone sarcoma at time of sampling who later were found not to have osteosarcoma. Fifteen of 28 patients without overt metastases at primary diagnosis (54%) were positive, 12 of whom had localized high-grade primary tumors in the extremity. Four of these have relapsed compared with none of 10 negative patients. In the group of 22 patients with extremity localized nonmetastatic osteosarcoma, information was available on the histologic response to preoperative chemotherapy in15 patients. None of the three patients in the bone marrow^negative group who had a poor response to chemotherapy have relapsed, whereas two of the four poor responders in the bone marrow^positive cohort are deadof disease. Among12 patients with overt metastasis at primary diagnosis, 11 (92%) were positive in bone marrow with a very high number of osteosarcoma cells. The immunomagnetically isolated cells were further characterized by the use of fluorescent latex microparticles with surface-bound antibodies targeting different membrane markers. Moreover, in cases with numerous osteosarcoma cells in bone marrow attempts to grow the selected cells in vitro were successful in two of eight attempts, and in two of five cases, isolated cells produced tumors with osteosarcoma characteristics in nude mice. In conclusion, already at primary diagnosis, a very high fraction of osteosarcoma patients had malignant cells in bone marrow, and a correlation between the presence of tumor cells, clinical stage, and disease progression was found. The data show the clinical potential of this immunomagnetic method. Attempts to subgroup osteosarcoma patients for more individualized treatment based on the presence of micrometastatic cells should be studied in a larger cohort of patients.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Hematogenous Micrometastases in Osteosarcoma Patients

Bruland

Høifødt

Sæter³

et al. 2005

Clinical Cancer Research

100

View full text Add to dashboard Cite

show abstract

“…Primary, polyclonal Immunomagnetic cell separation MOC-31 (IQ Corporation BV, Groningen, The Netherlands) is an IgG1 class antibody that binds to the EPCAM antigen, which is consistently expressed in most epithelial cells [9]. The high-affinity monoclonal antibody 9.2.27, which was originally developed against melanoma [10], recognizes an epitope on the high molecular weight melanoma-associated antigen and has also been shown to bind some subgroups of sarcoma, including osteosarcoma [11,12]. The antibodies were conjugated to superparamagnetic particles coated with polyclonal sheep-antimouse IgG particles (Dynabeads; Dynal A.S., Oslo, Norway).…”

Section: Western Blot Analysismentioning

confidence: 99%

Osteoblast-induced EGFR/ERBB2 signaling in androgen-sensitive prostate carcinoma cells characterized by multiplex kinase activity profiling

Bratland

Boender

Høifødt

et al. 2009

Clin Exp Metastasis

View full text Add to dashboard Cite

Bone metastases in prostate cancer are predominantly osteoblastic. To study regulatory mechanisms underlying the establishment of prostate cancer within an osteoblastic microenvironment, human androgen-sensitive prostate carcinoma cells (LNCaP) were treated with culture medium conditioned by human osteoblast-derived sarcoma cells (OHS), and activated signalling pathways in the carcinoma cells were analyzed using microarrays with tyrosine kinase substrates. Network interaction analysis of substrates with significantly increased phosphorylation levels revealed that signalling pathways mediated by EGFR and ERBB2 were activated in LNCaP cells under OHS influence but also by androgen treatment. Activation of EGFR/ERBB2 signalling was also found in LNCaP cells in cocultures with OHS cells or osteoblastic cells that had been differentiated from human mesenchymal stem cells. Our experimental data suggests osteoblast-directed induction of signalling activity via EGFR and ERBB2 in prostate carcinoma cells and may provide a rationale for the use of EGFR or ERBB2 inhibition in systemic prevention or treatment of metastatic prostate cancer in the androgensensitive stage of the disease.

show abstract

“…The antibody binds to the 250 kD core glycoprotein of a chondroitin sulphate proteoglycan expressed primarily on human melanoma cells (12) but also on some sarcoma cells, including OHS cells (13). An isotype-matched irrelevant mouse MAb (Dako) was used as negative control.…”

Section: Monoclonal Antibodiesmentioning

confidence: 99%